Oligonucleotide · Gene silencing: BCL2 · developed by Sierra Oncology LLC - a GSK company
PNT2258 is a liposomal formulation of a 24-mer oligonucleotide that binds complementarily to the untranscribed DNA sequence upstream of BCL2 promoters. It interferes with DNA replication and transcription of the BCL2 gene, which is intended to restore apoptosis in BCL2-overexpressing tumor cells. It is being studied in Richter's Transformation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02226965 | Phase 2 | Lymphoma, Diffuse Large B-Cell | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Richter's Transformation
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →